Neem's Hill (NEEMS) Q2 2026 earnings summary

Executive summary

• Q2 2026 saw net sales of 3,292 KSEK, down from 3,841 KSEK year-over-year, with all sales from Animal Care.

• Treatment kit sales rose 52% in H1 2026, reflecting increased clinical activity and recurring revenue.

• The company completed all orders by period end and expanded its installed base to nearly 60 vetlQure systems.

• Academic recognition grew, with a 97% complete remission rate reported in an equine study using TSE technology.

• The company rebranded from Scandinavian ChemoTech AB to Neem's Hill AB, enhancing strategic flexibility.

Financial highlights

• Net sales for H1 2026 were 6,090 KSEK (6,313 KSEK in H1 2025).

• Operating loss for Q2 was -1,984 KSEK (-690 KSEK in Q2 2025); H1 operating loss was -3,363 KSEK (-3,257 KSEK in H1 2025).

• Net loss for Q2 was -2,622 KSEK (-943 KSEK in Q2 2025); H1 net loss was -4,195 KSEK (-4,265 KSEK in H1 2025).

• Cash flow from operating activities in Q2 was -1,780 KSEK (-504 KSEK in Q2 2025); H1 was -2,923 KSEK (-1,743 KSEK in H1 2025).

• Cash and cash equivalents at period end were 1,456 KSEK (517 KSEK in Q2 2025).

Outlook and guidance

• Focus remains on expanding the number of active vetlQure users and increasing utilization within the installed base.

• The company aims to support broader adoption through clinical evidence, academic partnerships, and customer support.

• Management expects recurring revenue to continue growing as more clinics adopt TSE technology.